{"id":"rituximab-infusion","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Infusion reactions"},{"rate":"5-15","effect":"Neutropenia"},{"rate":"5-10","effect":"Thrombocytopenia"},{"rate":"5-10","effect":"Anemia"},{"rate":"10-20","effect":"Infections"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Fever"},{"rate":"5-10","effect":"Chills"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rituximab targets the CD20 antigen expressed on the surface of B lymphocytes. Upon binding, it triggers multiple mechanisms of B cell destruction including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis. This results in rapid depletion of B cells, reducing autoimmune and malignant B cell populations.","oneSentence":"Rituximab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and direct apoptosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:28.142Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-Hodgkin's lymphoma (B-cell)"},{"name":"Chronic lymphocytic leukemia (CLL)"},{"name":"Rheumatoid arthritis"},{"name":"Granulomatosis with polyangiitis (GPA)"},{"name":"Microscopic polyangiitis (MPA)"}]},"trialDetails":[{"nctId":"NCT05139017","phase":"PHASE2, PHASE3","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-14","conditions":"DLBCL, Diffuse Large B-Cell Lymphoma","enrollment":290},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT03844061","phase":"PHASE2","title":"Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2019-07-29","conditions":"Systemic Sclerosis","enrollment":30},{"nctId":"NCT06717347","phase":"PHASE3","title":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-01-27","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1046},{"nctId":"NCT07492407","phase":"","title":"CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2026-04","conditions":"MZL","enrollment":131},{"nctId":"NCT01842386","phase":"PHASE1","title":"Rituximab for Anti-cytokine Autoantibody-Associated Diseases","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-04-29","conditions":"Pulmonary Alveolar Proteinosis (PAP), Severe Mucocutaneous Candidiasis","enrollment":7},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":"Follicular Lymphoma (FL)","enrollment":109},{"nctId":"NCT00977977","phase":"PHASE2","title":"Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2010-12-22","conditions":"Nephrotic Syndrome, Proteinuria, Autoimmune Disease","enrollment":30},{"nctId":"NCT04384484","phase":"PHASE3","title":"Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ADC Therapeutics S.A.","startDate":"2020-09-16","conditions":"Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":440},{"nctId":"NCT06821542","phase":"PHASE3","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-04","conditions":"Chronic Graft-versus-host-disease","enrollment":9},{"nctId":"NCT04998669","phase":"PHASE2","title":"Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma","status":"RECRUITING","sponsor":"Juan P. Alderuccio, MD","startDate":"2022-02-11","conditions":"Follicular Lymphoma","enrollment":100},{"nctId":"NCT06890884","phase":"PHASE2","title":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-11","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":594},{"nctId":"NCT07226843","phase":"PHASE1","title":"A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers","status":"NOT_YET_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-02","conditions":"Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma","enrollment":360},{"nctId":"NCT01011920","phase":"PHASE2","title":"Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2009-11","conditions":"Central Nervous System Lymphoma","enrollment":227},{"nctId":"NCT03684980","phase":"EARLY_PHASE1","title":"LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-11-14","conditions":"Central Nervous System Lymphoma","enrollment":58},{"nctId":"NCT06561360","phase":"PHASE2","title":"A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-09-09","conditions":"Hairy Cell Leukemia","enrollment":86},{"nctId":"NCT06599307","phase":"PHASE2","title":"The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis","status":"RECRUITING","sponsor":"Cairo University","startDate":"2024-08-01","conditions":"Secondary Progressive Multiple Sclerosis (SPMS)","enrollment":46},{"nctId":"NCT04404283","phase":"PHASE3","title":"Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2020-08-20","conditions":"Diffuse Large B-cell Lymphoma","enrollment":238},{"nctId":"NCT05624554","phase":"PHASE3","title":"A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-03-16","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":300},{"nctId":"NCT05011422","phase":"PHASE1","title":"Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2022-11-03","conditions":"Pediatric Hematologic Malignancies","enrollment":50},{"nctId":"NCT05947851","phase":"PHASE3","title":"A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-08-08","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma","enrollment":735},{"nctId":"NCT04644016","phase":"PHASE2","title":"Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-11-20","conditions":"AML, ALL, MDS","enrollment":31},{"nctId":"NCT06510309","phase":"PHASE2","title":"Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"Gottfried von Keudell, MD PhD","startDate":"2026-02-11","conditions":"Lymphoma, Marginal Zone Lymphoma, MZL","enrollment":33},{"nctId":"NCT07410039","phase":"PHASE4","title":"Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-02-01","conditions":"Neuromyelitis Optica Spectrum Disorder Attack","enrollment":200},{"nctId":"NCT04075292","phase":"PHASE3","title":"Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-01-20","conditions":"Untreated Chronic Lymphocytic Leukemia","enrollment":155},{"nctId":"NCT05800366","phase":"PHASE2","title":"A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Jennifer Crombie, MD","startDate":"2023-04-06","conditions":"Lymphoma, Lymphoma, Large B-Cell, Diffuse","enrollment":41},{"nctId":"NCT07294677","phase":"PHASE1, PHASE2","title":"CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2026-03-17","conditions":"Leukemia, Lymphoma","enrollment":104},{"nctId":"NCT03789240","phase":"PHASE2","title":"Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-22","conditions":"Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL","enrollment":33},{"nctId":"NCT07157787","phase":"PHASE2","title":"Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-09-19","conditions":"Primary Membranous Nephropathy","enrollment":30},{"nctId":"NCT04285567","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-05-28","conditions":"Chronic Lymphocytic Leukemia (CLL)","enrollment":166},{"nctId":"NCT06191744","phase":"PHASE3","title":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2024-02-05","conditions":"Follicular Lymphoma (FL)","enrollment":1095},{"nctId":"NCT06508658","phase":"PHASE3","title":"A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2024-08-13","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":360},{"nctId":"NCT05605899","phase":"PHASE3","title":"Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2023-02-10","conditions":"High-risk Large B-cell Lymphoma (LBCL)","enrollment":300},{"nctId":"NCT06364423","phase":"PHASE1, PHASE2","title":"Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-03","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell, B-Lymphocytic Leukemia, Chronic, B-Cell Chronic Lymphocytic Leukemia","enrollment":132},{"nctId":"NCT06078696","phase":"PHASE1, PHASE2","title":"Siplizumab for Sickle Cell Disease Transplant","status":"TERMINATED","sponsor":"Columbia University","startDate":"2023-09-28","conditions":"Anemia, Sickle Cell","enrollment":1},{"nctId":"NCT03919175","phase":"PHASE2","title":"Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2019-09-01","conditions":"Lymphoma, Follicular Lymphoma, Follicular Lymphoma, Grade 1","enrollment":18},{"nctId":"NCT04268277","phase":"PHASE2","title":"Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY","status":"TERMINATED","sponsor":"University of Ulm","startDate":"2022-03-01","conditions":"Marginal Zone Lymphoma","enrollment":22},{"nctId":"NCT06655896","phase":"PHASE2","title":"Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-10-29","conditions":"Scleroderma, Diffuse","enrollment":96},{"nctId":"NCT05991388","phase":"PHASE2, PHASE3","title":"A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2024-05-02","conditions":"B-cell Non Hodgkin Lymphoma","enrollment":210},{"nctId":"NCT05898308","phase":"PHASE4","title":"Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2024-12-04","conditions":"Pemphigus, Dermatologic Disease","enrollment":133},{"nctId":"NCT06475235","phase":"PHASE1","title":"Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-10-18","conditions":"Lymphoma, Primary Central Nervous System Lymphoma","enrollment":15},{"nctId":"NCT06854003","phase":"PHASE2","title":"BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Christine Ryan","startDate":"2025-04-22","conditions":"Mantle Cell Lymphoma, Lymphoma","enrollment":60},{"nctId":"NCT04421560","phase":"PHASE1, PHASE2","title":"Pembrolizumab, Ibrutinib and Rituximab in PCNSL","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-08-01","conditions":"Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer","enrollment":37},{"nctId":"NCT03929601","phase":"PHASE2","title":"Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2023-10-30","conditions":"Type 1 Diabetes Mellitus","enrollment":74},{"nctId":"NCT06563596","phase":"PHASE2","title":"Epco, Zanu, Ritux for R/R FL or MZL","status":"RECRUITING","sponsor":"Reid Merryman, MD","startDate":"2025-01-21","conditions":"Follicular Lymphoma, Lymphoma, Non-Hodgkin Lymphoma","enrollment":45},{"nctId":"NCT03295383","phase":"PHASE3","title":"Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2019-07-11","conditions":"Severe Forms of Mucous Membrane Pemphigoid","enrollment":130},{"nctId":"NCT07418190","phase":"PHASE2","title":"Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-02-01","conditions":"Relapsed/Refractory Follicular Lymphoma","enrollment":33},{"nctId":"NCT07410520","phase":"PHASE2","title":"PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-02-07","conditions":"Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)","enrollment":50},{"nctId":"NCT03949855","phase":"PHASE2","title":"Belimumab With Rituximab for Primary Membranous Nephropathy","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-03-06","conditions":"Membranous Nephropathy, Nephrotic Syndrome","enrollment":58},{"nctId":"NCT06644183","phase":"PHASE1, PHASE2","title":"Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)","status":"RECRUITING","sponsor":"Jennifer R. Brown, MD, PhD","startDate":"2025-03-19","conditions":"Leukemia, Relapsed Leukemia, Chronic Lymphocytic Leukemia","enrollment":64},{"nctId":"NCT03274492","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-11-16","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1000},{"nctId":"NCT06097364","phase":"PHASE3","title":"A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-11-14","conditions":"Follicular Lymphoma (FL)","enrollment":733},{"nctId":"NCT06230224","phase":"PHASE3","title":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-02-15","conditions":"B-Cell Non-Hodgkin Lymphoma (B-NHL)","enrollment":216},{"nctId":"NCT06350318","phase":"PHASE2","title":"Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-04-19","conditions":"Follicular Lymphoma, Marginal Zone Lymphoma, B-Cell Lymphoma","enrollment":43},{"nctId":"NCT06564038","phase":"PHASE1, PHASE2","title":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-01-30","conditions":"Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma","enrollment":276},{"nctId":"NCT06091865","phase":"PHASE3","title":"A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-13","conditions":"Diffuse Large B-cell Lymphoma (DLBCL)","enrollment":904},{"nctId":"NCT04884035","phase":"PHASE1","title":"Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma","status":"RECRUITING","sponsor":"Celgene","startDate":"2021-09-15","conditions":"Lymphoma, B-Cell","enrollment":174},{"nctId":"NCT05660369","phase":"PHASE1","title":"CARv3-TEAM-E T Cells in Glioblastoma","status":"RECRUITING","sponsor":"Marcela V. Maus, M.D.,Ph.D.","startDate":"2023-03-22","conditions":"Glioblastoma, Malignant Glioma, Recurrent Glioblastoma","enrollment":21},{"nctId":"NCT06983821","phase":"PHASE3","title":"Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2025-11-10","conditions":"Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA)","enrollment":36},{"nctId":"NCT03579875","phase":"PHASE2","title":"Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2018-11-13","conditions":"Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes","enrollment":48},{"nctId":"NCT06834373","phase":"PHASE2","title":"Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-04-02","conditions":"Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent ALK-Positive Large B-Cell Lymphoma","enrollment":41},{"nctId":"NCT04784052","phase":"PHASE1, PHASE2","title":"Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab","status":"RECRUITING","sponsor":"Porteus, Matthew, MD","startDate":"2021-12-07","conditions":"Fanconi Anemia","enrollment":18},{"nctId":"NCT07233330","phase":"PHASE2","title":"Obinutuzumab in Adult Rituximab-Dependent Nephrotic Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2026-02","conditions":"Nephrotic Syndrome，Idiopathic","enrollment":10},{"nctId":"NCT07355699","phase":"PHASE4","title":"Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"Beijing Tongren Hospital","startDate":"2025-11-25","conditions":"Marginal Zone Lymphoma(MZL)","enrollment":88},{"nctId":"NCT06688331","phase":"PHASE2","title":"Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody","status":"RECRUITING","sponsor":"PolTREG S.A.","startDate":"2025-03-12","conditions":"Presymptomatic Diabetes Type 1 (Stage 1), Diabetes Mellitus, Type I, Diabetes Mellitus, Type 1","enrollment":150},{"nctId":"NCT05737628","phase":"PHASE1","title":"First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228","status":"ACTIVE_NOT_RECRUITING","sponsor":"Byondis B.V.","startDate":"2024-03-04","conditions":"Lymphoma","enrollment":17},{"nctId":"NCT03697512","phase":"PHASE2","title":"MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2019-09-27","conditions":"Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma","enrollment":175},{"nctId":"NCT05735834","phase":"PHASE3","title":"Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2024-05-21","conditions":"Splenic Marginal Zone Lymphoma","enrollment":122},{"nctId":"NCT03571321","phase":"PHASE1","title":"Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2019-05-28","conditions":"Acute Lymphoblastic Leukemia, ALL, Childhood, ALL","enrollment":15},{"nctId":"NCT04843904","phase":"PHASE1","title":"Safe Accelerated Venetoclax Escalation in CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-04-14","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":40},{"nctId":"NCT02171104","phase":"PHASE2","title":"MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2014-07-10","conditions":"Mucopolysaccharidosis Disorders, Hurler Syndrome, Hunter Syndrome","enrollment":149},{"nctId":"NCT04047628","phase":"PHASE3","title":"Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-19","conditions":"Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis","enrollment":156},{"nctId":"NCT06220032","phase":"PHASE3","title":"Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma","status":"RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2024-08-15","conditions":"DLBCL - Diffuse Large B Cell Lymphoma","enrollment":324},{"nctId":"NCT05249959","phase":"PHASE2","title":"Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2022-03-21","conditions":"Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma","enrollment":49},{"nctId":"NCT02990286","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2017-01-20","conditions":"Lung Disease, Interstitial","enrollment":122},{"nctId":"NCT01350882","phase":"PHASE3","title":"Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2008-10","conditions":"Humoral Rejection in Kidney Transplantation","enrollment":40},{"nctId":"NCT05783609","phase":"PHASE2","title":"Epcoritamab and Rituximab for First-line Follicular Lymphoma","status":"RECRUITING","sponsor":"Reid Merryman, MD","startDate":"2023-06-21","conditions":"Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult","enrollment":100},{"nctId":"NCT05952024","phase":"PHASE2","title":"Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-07-16","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT02296918","phase":"PHASE1","title":"Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2014-12-22","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia","enrollment":69},{"nctId":"NCT07189065","phase":"PHASE2","title":"A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","startDate":"2025-11-27","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":150},{"nctId":"NCT00692939","phase":"PHASE1, PHASE2","title":"Autologous Stem Cell Transplantation for Crohn's Disease","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2012-06-26","conditions":"Crohn's Disease","enrollment":20},{"nctId":"NCT03952637","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis","status":"RECRUITING","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"2019-08-19","conditions":"Lysosomal Diseases, Gangliosidosis, GM1","enrollment":54},{"nctId":"NCT04745728","phase":"PHASE3","title":"Different Immunosuppressive Treatment in iMN","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2021-04-14","conditions":"Idiopathic Membranous Nephropathy","enrollment":200},{"nctId":"NCT05494593","phase":"PHASE4","title":"A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2023-02-28","conditions":"Mucopolysaccharidosis (MPS), Hunter Syndrome","enrollment":""},{"nctId":"NCT07269639","phase":"PHASE1, PHASE2","title":"Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2026-01-01","conditions":"Large B-Cell Lymphoma (LBCL)","enrollment":20},{"nctId":"NCT06803693","phase":"PHASE2","title":"Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-04-01","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":152},{"nctId":"NCT07206823","phase":"NA","title":"Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-09-01","conditions":"Primacy Immune Thrombocytopenia","enrollment":30},{"nctId":"NCT07259122","phase":"PHASE2","title":"A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-12-30","conditions":"Waldenström Macroglobulinemia (WM)","enrollment":43},{"nctId":"NCT03391466","phase":"PHASE3","title":"Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2018-01-25","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":359},{"nctId":"NCT06362044","phase":"","title":"A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan","status":"COMPLETED","sponsor":"AbbVie","startDate":"2023-06-07","conditions":"Chronic Lymphocytic Leukemia","enrollment":89},{"nctId":"NCT05136976","phase":"PHASE3","title":"Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2023-06-29","conditions":"Anti-MAG Neuropathy","enrollment":90},{"nctId":"NCT06561347","phase":"PHASE2","title":"Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-12-20","conditions":"Waldenstrom Macroglobulinemia","enrollment":55},{"nctId":"NCT02433522","phase":"PHASE3","title":"Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-03-31","conditions":"ANCA-associated Vasculitides","enrollment":97},{"nctId":"NCT06047171","phase":"PHASE2","title":"Rescue of Nephrons With ALE.F02 (RENAL-F02)","status":"RECRUITING","sponsor":"Alentis Therapeutics AG","startDate":"2023-09-07","conditions":"Glomerulonephritis Rapidly Progressive","enrollment":80},{"nctId":"NCT06186219","phase":"PHASE1","title":"Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2024-04-10","conditions":"Tophaceous Gout","enrollment":2},{"nctId":"NCT00748644","phase":"PHASE3","title":"Efficacy Study of Two Treatments in the Remission of Vasculitis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-10","conditions":"Wegener Granulomatosis, Microscopic Polyangiitis","enrollment":117},{"nctId":"NCT03069703","phase":"PHASE2","title":"Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-02-05","conditions":"Invasive Pneumococcal Infection","enrollment":96},{"nctId":"NCT03164473","phase":"PHASE3","title":"Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis.","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-03-07","conditions":"Eosinophilic Granulomatosis With Polyangiitis","enrollment":98},{"nctId":"NCT02727803","phase":"PHASE2","title":"Personalized NK Cell Therapy in CBT","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-05-19","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia","enrollment":100},{"nctId":"NCT04318678","phase":"PHASE1","title":"CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2020-07-29","conditions":"AML/MDS, B-ALL, T-ALL","enrollment":108}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":424,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Mabthera","Rituxan"],"phase":"marketed","status":"active","brandName":"Rituximab infusion","genericName":"Rituximab infusion","companyName":"Centre Hospitalier Universitaire de Saint Etienne","companyId":"centre-hospitalier-universitaire-de-saint-etienne","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rituximab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and direct apoptosis. Used for Non-Hodgkin's lymphoma (B-cell), Chronic lymphocytic leukemia (CLL), Rheumatoid arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}